AI-generated compounds hit specific cell types and outperform conventional screening

Article excerpt

The classical drug discovery paradigm begins with a known molecular target: a protein whose modulation is expected to reverse the course of a disease. However, in many pathologies, such a target does not always exist or is not sufficiently characterized.